Home Newsfeeds Piper Sandler Downgrades Shift Technologies to Neutral

Piper Sandler Downgrades Shift Technologies to Neutral

Piper Sandler analyst Alexander Potter downgrades Shift Technologies (NASDAQ:SFT) from Overweight to Neutral.

byBenzinga Newsdesk

February 16, 2023

1 minute read

Piper Sandler analyst Alexander Potter downgrades Shift Technologies (NASDAQ:SFT) from Overweight to Neutral.

Telsey Advisory Group Maintains Market Perform on Ross Stores, Raises Price Target to $120

By Benzinga Newsdesk

November 18, 6:08 AM

Telsey Advisory Group analyst Dana Telsey maintains Ross Stores (NASDAQ:ROST) with a Market Perform and raises the price target from $80 to $120.

ROST

Citigroup Maintains Neutral on Qurate Retail, Lowers Price Target to $3

By Benzinga Newsdesk

July 7, 8:14 AM

Citigroup analyst Jason Bazinet maintains Qurate Retail (NASDAQ:QRTEA) with a Neutral and lowers the price target from $4 to $3.

QRTEA

News

Verona Pharma to Present Expanded Analyses of Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

By Benzinga Newsdesk

May 2, 3:32 AM

Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces 12 abstracts, including a mini symposium, and

VRNA

LeMaitre Vascular Q4 EPS $0.25 Misses $0.26 Estimate, Sales $41.00M Beat $40.99M Estimate

By Bill Haddad

February 23, 4:58 PM

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.26 by 3.85 percent. This is a 10.71 percent decrease over earnings of $0.28 per share from

LMAT

Piper Sandler Downgrades Shift Technologies to Neutral

Related Posts

Telsey Advisory Group Maintains Market Perform on Ross Stores, Raises Price Target to $120

Citigroup Maintains Neutral on Qurate Retail, Lowers Price Target to $3

Verona Pharma to Present Expanded Analyses of Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

LeMaitre Vascular Q4 EPS $0.25 Misses $0.26 Estimate, Sales $41.00M Beat $40.99M Estimate